International Life Sciences Awards 2021

12 GHP / International Life Sciences Awards 2021 , Jul21799 As Biotechflow Ltd celebrates success at the GHP International Life Science Awards 2021 for its pioneering work in the field of Expanded Bed Adsorption Chromatography, CFO Debbie Miller gives us an insight into the results of Founder Dr Martin Hofmann’s 30 years of lifechanging research. Best Expanded Bed Adsorption Chromatography Solutions Manufacturer 2021 Founded in 2010 by Dr Martin Hofmann, Biotechflow Ltd is a Gloucestershire UK-based company specialising in the original design, manufacture, installation, and validation of Expanded Bed Adsorption Chromatography (EBA) columns and accessories (as well as other novel products) for cGMP biopharmaceutical downstream processing. EBA is a chromatographic technique that isolates and purifies drugs/therapeutics directly from biomass In recent years, EBA has undergone a revolution pioneered by Biotechflow, who are dedicated to making the process significantly more efficient and effective. “Working within this fast moving industry we constantly keep abreast of new innovations by regular communication with international drug producers and attending industry standard conferences” says Dr Martin Hofmann. “We are constantly adding to our portfolio of granted patents for the EBA and DSP, of which we have 5 of in the USA and Europe.” After thirty years of cutting edge work with global biotech and pharmaceutical industries, Biotechflow has developed its revolutionary EBA column that is fed directly from the bioreactor with unclarified and the undiluted biomass. The single step chromatography column process which is unique in its market, isolates the product without the need for clarification, centrifugation, filtration, intermediate storage, packing to HETP approved standard, or any other costly or time-consuming processes. As speed, efficiency and low environmental impacts become increasingly important alongside cost-efficiency regarding the production of human injectables, the EBA technique has been proven to reduce process times, clean room space and buffer consumption by a third, in comparison to traditional methods. Thanks to the seamless transfer of unclarified biomass directly from bioreactor into the patented single column, Biotechflow’s clientele have scaled up from laboratory to commercial scale production of monoclonal antibodies (mAbs) recombinant therapeutic poly peptides and proteins etc. Biotechflow’s equipment has been installed at commercial scale (post phase iii)on 4 continents facilitating the isolation at high concentration of pure product from 2-5000 litres of biomass as well as being renouned for its validation documentation and post installation service. Biotechflow is internationally equipped to deal with the increasing attention and demand for its unique product. “We have an amazing team of people with the combined experience of over 100 years in DSP, who work hard for our clients providing the information and equipment they need to help them manufacture and develop their products,” says Debbie. Biotechflow continues to play it’s vital role at the helm of DSP for the pharmaceutical industry of today.This is now critical in regard to the fight against Covid-19, the company has a lot to celebrate – not least, its recent award at the Global Health & Pharma International Life Science Awards 2021. We look forward to witnessing many more successes that lie ahead for Biotechflow which will undoubtedly continue to shape the future of modern pharmaceuticals for the better. Contact: [email protected] Company: Biotechflow Ltd Web: www.biotechflow.com